2023 Annual Stakeholders Meeting Pre-Workshops

Register today for one of two in-depth workshops happening before the kick-off of KHI's Annual Stakeholders Meeting. The workshops will be held simultaneously on Wednesday, September 6, 2023, from 1:00 - 3:30 pm EDT at the Grand Hyatt Washington, D.C. Spots are limited, and registration is currently open to KHI members only. Non-KHI members will be waitlisted.

*UPDATE: Registration is now closed for the pre-workshops. If you have any concerns, please email khi@asn-online.org.*

APOL1 Kidney Disease: A Roadmap from Community Awareness and Screening to Clinical Trial Participation

Join the launch of KHI's APOL1 Kidney Disease Roadmap to the kidney community. APOL1 is a disease that disproportionately impacts people with recent African ancestry. This discussion and workshop will highlight roadmap action items and ways to increase disease awareness, increase genetic testing, and improve clinical study participation. This focus on APOL1 Kidney Disease provides a foundation for other kidney diseases where clinical trial enrollment and participation remain challenging. This workshop aims to gather your thoughts and experiences to inform how KHI can further engage community-based organizations. Registered workshop participants will receive an early copy of the roadmap. 

 SGLT2 Inhibitors: Conducting Pediatric Clinical Trials

Landmark trials conducted in the last few years have demonstrated that SGLT2 Inhibitors are safe and effective at slowing the rate of progression of kidney diseases ranging from diabetic kidney disease to IgA nephropathy. When added to the current standard of care, these drugs lower the risk of kidney failure and death. However, these clinical trials were conducted in adult patients. It is unknown if the significant health benefits of SGLT2 inhibitors apply to pediatric patients with chronic kidney disease. In July 2023, together with KHI member, NephCure, and key stakeholders from the United States and Europe, KHI organized a workshop to discuss the need for clinical trials of SGLT2 inhibitors in pediatric chronic kidney disease. This session will highlight the key conclusions of the workshop. It will solicit input from the KHI community on how to foster awareness of the need for clinical trials of SGLT2 inhibitors in the pediatric nephrology community and patient populations and how to maximize the feasibility of these studies. Registered workshop participants will receive updates from the joint NephCure workshop to help prepare for this discussion.